Tactile Systems: 3 Key Takeaways for Long-Term Investors

Impact · against what's priced in

Tactile Systems (TCMD) provides positive catalysts through an upward revision of full-year EBITDA guidance and double-digit revenue growth in its lymphedema segment. The implementation of AI to halve medical record review times suggests a structural improvement in revenue recognition speed.

TCMD+0.60

No priced-in read yet

In context

The company raised its full-year adjusted EBITDA guidance to $50 million–$52 million and reported 13% YoY growth in lymphedema revenue to $81.8 million, alongside a 50% reduction in medical record review times.

Read from the article alone

• earnings
• healthcare
• guidance
• TCMD
• ai ops
• ebitda
• margin expansion
• medical devices

Search tags